ZyVersa Therapeutics Highlights Publication Indicating That
NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications (e.g., Type 2 Diabetes, Hypertension, Heart Disease)....
Source: globenewswire.com
Dave Schemelia News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Dave Schemelia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Dave Schemelia Today - Breaking & Trending Today
ZyVersa Therapeutics Announces Peer-Reviewed Article
Activation of the inflammasome/ASC speck pathway has a vital role in synaptic degeneration in Alzheimer’s Disease (AD)....
Source: globenewswire.com
ZyVersa Therapeutics Highlights Peer-Reviewed Article
NLRP3 Inflammasome Activation Is Linked to Brain Metastasis in Patients with Triple-Negative Breast Cancer. ...
Source: globenewswire.com
Cyrano Therapeutics Secures $9.0 Million Series B Financing to Advance Clinical Development of CYR-064 for Treatment of Post-Viral Smell Loss
Phase 2 FLAVOR clinical trial currently enrolling 150 patients to assess the safety and effectiveness of CYR-064 in treating patients with chronic smell loss following recovery from a viral infection
Source: eagletribune.com
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter
WESTON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical...
Source: globenewswire.com